Enliven Therapeutics (NASDAQ:ELVN) Trading Down 3.6% Following Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price fell 3.6% during trading on Monday after an insider sold shares in the company. The stock traded as low as $20.16 and last traded at $20.32. 15,170 shares were traded during mid-day trading, a decline of 93% from the average session volume of 207,792 shares. The stock had previously closed at $21.08.

Specifically, Director Richard A. Heyman sold 1,270 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the transaction, the director now directly owns 137,155 shares in the company, valued at $2,741,728.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Richard A. Heyman sold 1,270 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $19.99, for a total transaction of $25,387.30. Following the sale, the director now owns 137,155 shares of the company’s stock, valued at $2,741,728.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $15.69, for a total transaction of $188,280.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 763,661 shares of company stock worth $13,213,762. Insiders own 45.80% of the company’s stock.

Analysts Set New Price Targets

Separately, Mizuho started coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

Enliven Therapeutics Price Performance

The company has a market cap of $770.03 million, a PE ratio of -8.53 and a beta of 1.06. The firm has a 50-day simple moving average of $16.94 and a two-hundred day simple moving average of $14.29.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. BlackRock Inc. raised its holdings in shares of Enliven Therapeutics by 4,476.0% in the 2nd quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock worth $31,564,000 after purchasing an additional 1,512,680 shares during the period. State Street Corp raised its stake in Enliven Therapeutics by 4,847.5% during the second quarter. State Street Corp now owns 466,251 shares of the company’s stock worth $9,516,000 after acquiring an additional 456,827 shares during the period. Geode Capital Management LLC raised its position in shares of Enliven Therapeutics by 1,071.1% during the 2nd quarter. Geode Capital Management LLC now owns 414,444 shares of the company’s stock worth $8,459,000 after purchasing an additional 379,056 shares during the period. Northern Trust Corp bought a new stake in Enliven Therapeutics in the second quarter valued at $3,999,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Enliven Therapeutics by 150.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 156,631 shares of the company’s stock valued at $2,140,000 after purchasing an additional 94,169 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.